Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Asia Pacific Non-Randomized, Open-Label Phase II Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab (Erbitux) or FOLFOX Plus Cetuximab as First-Line Therapy in Subjects With KRAS Wild-Type Metastatic Colorectal Cancer (APEC-Study).

Next Previous
Trial Profile

An Asia Pacific Non-Randomized, Open-Label Phase II Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab (Erbitux) or FOLFOX Plus Cetuximab as First-Line Therapy in Subjects With KRAS Wild-Type Metastatic Colorectal Cancer (APEC-Study).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms APEC
  • Sponsors Merck KGaA

Most Recent Events

  • 03 Jul 2021 Results of subgroup analyses from EREBUS, ERBITAG and CEBIFOX assessing overall survival with cetuximab every 2 weeks vs standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer APEC presented at the 23rd World Congress on Gastrointestinal Cancer
  • 05 Jun 2018 Results (n=167) of subgroup analysis assessing the impact of tumor side in the APEC study population with RAS wt mCRC presented at the 54th Annual Meeting of the American Society of Clinical Oncology
  • 20 Jan 2018 Results of subgroup analysis assessing impact of tumor side, presented at the 2018 Gastrointestinal Cancers Symposium.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top